JP2023512036A5 - - Google Patents

Info

Publication number
JP2023512036A5
JP2023512036A5 JP2022546059A JP2022546059A JP2023512036A5 JP 2023512036 A5 JP2023512036 A5 JP 2023512036A5 JP 2022546059 A JP2022546059 A JP 2022546059A JP 2022546059 A JP2022546059 A JP 2022546059A JP 2023512036 A5 JP2023512036 A5 JP 2023512036A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nectin
binding protein
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022546059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512036A (ja
JP7682553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/051938 external-priority patent/WO2021151984A1/en
Publication of JP2023512036A publication Critical patent/JP2023512036A/ja
Publication of JP2023512036A5 publication Critical patent/JP2023512036A5/ja
Priority to JP2025077110A priority Critical patent/JP2025121970A/ja
Application granted granted Critical
Publication of JP7682553B2 publication Critical patent/JP7682553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022546059A 2020-01-31 2021-01-28 癌の処置 Active JP7682553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077110A JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968175P 2020-01-31 2020-01-31
US62/968,175 2020-01-31
PCT/EP2021/051938 WO2021151984A1 (en) 2020-01-31 2021-01-28 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077110A Division JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Publications (3)

Publication Number Publication Date
JP2023512036A JP2023512036A (ja) 2023-03-23
JP2023512036A5 true JP2023512036A5 (cg-RX-API-DMAC7.html) 2024-02-05
JP7682553B2 JP7682553B2 (ja) 2025-05-26

Family

ID=74494891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022546059A Active JP7682553B2 (ja) 2020-01-31 2021-01-28 癌の処置
JP2025077110A Pending JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077110A Pending JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Country Status (9)

Country Link
US (2) US12594343B2 (cg-RX-API-DMAC7.html)
EP (2) EP4096717B1 (cg-RX-API-DMAC7.html)
JP (2) JP7682553B2 (cg-RX-API-DMAC7.html)
CN (1) CN114845740B (cg-RX-API-DMAC7.html)
AU (2) AU2021213421B2 (cg-RX-API-DMAC7.html)
CA (1) CA3160557A1 (cg-RX-API-DMAC7.html)
DK (1) DK4096717T3 (cg-RX-API-DMAC7.html)
ES (1) ES3014740T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021151984A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
JP7904824B2 (ja) * 2020-09-15 2026-08-13 シンアフィックス ビー.ブイ. 抗体-エクサテカンコンジュゲート
JP2024501121A (ja) * 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4086284A1 (en) * 2021-05-07 2022-11-09 Emergence Therapeutics AG Anti-nectin-4 antibody exatecan conjugates
CN117500528A (zh) * 2021-06-18 2024-02-02 北京海步医药科技有限公司 连接子及其缀合物
MX2024008036A (es) * 2021-12-28 2024-07-15 Beigene Switzerland Gmbh Conjugados de anticuerpo y farmaco.
US20250205353A1 (en) * 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
WO2023227660A1 (en) * 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
JP2025519421A (ja) * 2022-06-09 2025-06-26 ベイジーン スイッツァランド ゲーエムベーハー 抗体薬物複合体
US20230408497A1 (en) * 2022-06-20 2023-12-21 Sysmex Corporation Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
WO2024028258A1 (en) * 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
EP4324849A1 (en) * 2022-08-18 2024-02-21 Emergence Therapeutics AG Humanized anti-nectin-4 antibodies
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
WO2024102523A1 (en) * 2022-11-09 2024-05-16 Obi Pharma, Inc. Glycosynthase variants for antibody-drug conjugate engineering
WO2024191598A1 (en) * 2023-03-10 2024-09-19 Emory University Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
AU2024304180A1 (en) * 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン-4抗体及び抗体-薬物コンジュゲート
EP4735047A1 (en) * 2023-06-28 2026-05-06 Université de Tours Pegylated linkers and uses thereof
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
KR20260094408A (ko) * 2023-10-13 2026-06-22 주식회사 리가켐바이오사이언스 토포이소머라아제 i 저해제를 포함하는 항-클라우딘 18.2 항체-약물 접합체 및 이의 용도
WO2025083067A1 (en) * 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
FR3155709A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
FR3155708A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
US20250186604A1 (en) * 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
EP4732850A1 (en) * 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1999061061A1 (fr) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
EP2907525B1 (en) 2007-11-21 2018-05-16 University Of Georgia Research Foundation, Inc. Dibenzocyclooctene-compounds for bioorthogonal reactions
US20110301056A1 (en) 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
ES2874306T3 (es) * 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
EP3733209A1 (en) 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3546448B1 (en) 2016-11-25 2022-04-06 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
TWI870338B (zh) 2017-06-05 2025-01-21 美商艾澤西公司 粘附分子-4結合蛋白及其使用方法
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
RS64961B1 (sr) * 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
AU2020364959B2 (en) 2019-10-07 2026-07-09 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for Nectin-4 and uses thereof
US20230025600A1 (en) 2019-11-25 2023-01-26 Agensys, Inc. Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
CN113527486B (zh) 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
IL298903A (en) 2020-06-18 2023-02-01 Bioatla Llc Antibodies against nectin-4 are conditionally active
KR20230060509A (ko) 2020-09-04 2023-05-04 노바록 바이오테라퓨틱스 리미티드 넥틴-4 항체 및 이의 용도
JP7904824B2 (ja) 2020-09-15 2026-08-13 シンアフィックス ビー.ブイ. 抗体-エクサテカンコンジュゲート
JP2024501121A (ja) 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
WO2023227660A1 (en) 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents

Similar Documents

Publication Publication Date Title
Lambert et al. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review
US20250281634A1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
Perez et al. Antibody–drug conjugates: current status and future directions
Senter Potent antibody drug conjugates for cancer therapy
JP2021102648A (ja) 抗folr1免疫複合体投与計画
Alley et al. Antibody–drug conjugates: targeted drug delivery for cancer
KR101783529B1 (ko) 항체-약물 접합체
JP2018520991A5 (cg-RX-API-DMAC7.html)
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
JP2018520091A5 (cg-RX-API-DMAC7.html)
Lee et al. Antibody-drug conjugates in gynecologic malignancies
JP2024501121A5 (cg-RX-API-DMAC7.html)
JP7264831B2 (ja) 抗globo h抗体を含有する抗体-薬物コンジュゲートおよびその使用
US20210283267A1 (en) Therapeutic methods using antibody drug conjugates (adcs)
Amani et al. ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies
Xie et al. Antibody-drug conjugates for the therapy of thoracic malignancies
Kommineni et al. Antibody drug conjugates: development, characterization, and regulatory considerations
JP2024539989A5 (cg-RX-API-DMAC7.html)
JP2025535447A5 (cg-RX-API-DMAC7.html)
KR20150032886A (ko) 항-etbr 항체 및 면역접합체
Auvert et al. Development of optimized exatecan-based immunoconjugates with potent antitumor efficacy in HER2-positive breast cancer
JPWO2021251459A5 (cg-RX-API-DMAC7.html)
Sevilla-Carrillo et al. Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology
Deng et al. Recent advances in antibody-drug conjugates for breast cancer treatment
JP2024528917A5 (cg-RX-API-DMAC7.html)